Anti-IL12/23 or anti-IL23 - Ustekinumab(University of Calgary)은 Crohn Disease 표적 항체로, Crohn Disease 영역에서 개발·상용화 중입니다. 작용기전: with high efficacy and safety profiles, sustained total skin clearance, and rapid onset of effect also to psoriasis patients who previously failed or experienced an inadequate resp. FDA 승인 또는 승인 단계 프로그램입니다. ClinicalTrials.gov 기준 4건의 관련 임상이 등록되어 있습니다.
Crohn Disease
Crohn Disease
Recruiting
with high efficacy and safety profiles, sustained total skin clearance, and rapid onset of effect also to psoriasis patients who previously failed or experienced an inadequate response to anti-TNF-α or anti-IL12/2
immune-mediated disease with either skin or joints manifestations, or both, and it has a major impact on quality of life
biomarkers independently predicted survival
bypass graft [CABG])
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Anti-IL12/23 or anti-IL23 - Ustekinumab(University of Calgary)은 Crohn Disease 표적 항체로, Crohn Disease 영역에서 개발·상용화 중입니다. 작용기전: with high efficacy and safety profiles, sustained total skin clearance, and rapid onset of effect also to psoriasis patients who previously failed or experienced an inadequate resp. FDA 승인 또는 승인 단계 프로그램입니다. ClinicalTrials.gov 기준 4건의 관련 임상이 등록되어 있습니다.
Crohn Disease
Crohn Disease
Recruiting
with high efficacy and safety profiles, sustained total skin clearance, and rapid onset of effect also to psoriasis patients who previously failed or experienced an inadequate response to anti-TNF-α or anti-IL12/2
immune-mediated disease with either skin or joints manifestations, or both, and it has a major impact on quality of life
biomarkers independently predicted survival
bypass graft [CABG])
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.